Home › NCT07125235

Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) Clinical Trial

Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) mHealth Randomized Controlled Hybrid Type I Effectiveness Implementation Trial

Who can join

Ages 18 to 70 · Men

Inclusion Criteria:

* Prescribed antiretroviral therapy (ART) with a tenofovir-based regimen.
* Documented virologic non-suppression, urine tenofovir testing without tenofovir detected, or self-reported adherence \<100%.
* Reports stimulant use.
* Has a mailing address within the U.S.
* Currently has a smartphone with photo capabilities.

Exclusion Criteria:

* Have any health condition that may interfere with participation or the ability to provide informed consent, including any debilitating or life-threatening conditions.
* Not prescribed ART.
* Unwilling to perform urine self-testing or to attend a local Quest site for viral load monitoring.
* Unable to provide a hair sample of \~50-100 strands of hair that are non-gray, not bleached, and at least 1cm in length

About the study

Men who are living with HIV and use stimulants face many challenges and barriers that may interfere with remembering to take their HIV medication. Forgetting to take HIV medication puts men living with HIV at a greater risk of becoming virally unsuppressed. Researchers are doing this study to test if a remote intervention can help participants improve remembering to take their HIV medications and reduce the HIV viral load among men living with HIV who use stimulants.

What is being tested

• reSTART Objective Adherence Self-Monitoring and Postive Affect mHealth Intervention (behavioral)
• urine tenofovir point-of-care self-test (device)

Sponsor: University of California, San Francisco · Participants: 270 · Started: Feb 9, 2026

Contact the study team

• Shivani Mahuvakar · Phone: 415-878-6384

Official record on ClinicalTrials.gov — NCT07125235

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.